Skip to main navigation

Investor Relations

Overview
Stock Information
News & Events
Financial Information
Corporate Governance
Shareholder Services

Presentations & Publications

Corporate Presentations

Corporate Presentation - September 2023

Sep 08, 2023

Data & Congress Presentations

A phase 1 first-in-human dose finding/randomized phase 2 study of IMM60 and pembrolizumab in advanced melanoma and NSCLC (IMP-MEL)

June 26, 2023

Source

Presented at ASCO 2023

IMP-MEL: A phase 1 first-in-human dose-finding study of a novel invariant natural killer T-cell agonist (iNKT) IMM60 in advanced melanoma and non-small-cell lung cancer (NSCLC)

November 10, 2022

Source

Presented at SITC 2022

A phase 1 first-in-human dose finding/randomized phase 2 study of IMM60 and pembrolizumab (PEM) in advanced melanoma and NSCLC (IMP-MEL)

October 3, 2022

Source

Presented at ASCO 2022

A Phase 1/2 study of Intratumoral INT230-6 Alone (IT-01) or in Combination with Pembrolizumab [KEYNOTE-A10] in Adult Subjects with Locally Advanced, Unresectable and Metastatic Solid Tumors Refractory to Therapy

July 21, 2022

Source

Presented at ASCO 2021

Early Results of Intratumoral INT230-6 Alone or in Combination with Ipilimumab in Subjects with Advanced Sarcomas

July 21, 2022

Source

Presented at ASCO 2021

Publications

Intratumoral Administration of a Novel Cytotoxic Formulation with Strong Tissue Dispersive Properties Regresses Tumor Growth and Elicits Systemic Adaptive Immunity in In Vivo Models

Co-delivery of PLGA Encapsulated Invariant NKT Cell Agonist with Antigenic Protein Induce Strong T Cell-Mediated Antitumor Immune Responses

PLGA Nanoparticles Co-encapsulating NY-ESO-1Peptides and IMM60 Induce Robust CD8 and CD4 T Cell and B Cell Responses

Featured Pages

Stock Information

Financial Information

Investor Tools

Print Page
RSS Feeds
Email Page
Email Alerts

Request Email Alerts

Copyright © All rights reserved Portage Biotech

Legal Links

Terms of Use Privacy policy Disclaimer

Facebook
Twitter
LinkedIn
Google+